Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2010 3
2012 2
2013 4
2014 1
2015 2
2016 3
2018 4
2019 3
2020 2
2021 7
2022 3
2023 7
2024 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission.
Burisch J, Zhao M, Odes S, De Cruz P, Vermeire S, Bernstein CN, Kaplan GG, Duricova D, Greenberg D, Melberg HO, Watanabe M, Ahn HS, Targownik L, Pittet VEH, Annese V, Park KT, Katsanos KH, Høivik ML, Krznaric Z, Chaparro M, Loftus EV Jr, Lakatos PL, Gisbert JP, Bemelman W, Moum B, Gearry RB, Kappelman MD, Hart A, Pierik MJ, Andrews JM, Ng SC, D'Inca R, Munkholm P. Burisch J, et al. Among authors: melberg ho. Lancet Gastroenterol Hepatol. 2023 May;8(5):458-492. doi: 10.1016/S2468-1253(23)00003-1. Epub 2023 Mar 2. Lancet Gastroenterol Hepatol. 2023. PMID: 36871566 Review.
Sphingolipids Are Depleted in Alcohol-Related Liver Fibrosis.
Thiele M, Suvitaival T, Trošt K, Kim M, de Zawadzki A, Kjaergaard M, Rasmussen DN, Lindvig KP, Israelsen M, Detlefsen S, Andersen P, Juel HB, Nielsen T, Georgiou S, Filippa V, Kuhn M, Nishijima S, Moitinho-Silva L, Rossing P, Trebicka J, Anastasiadou E, Bork P, Hansen T, Legido-Quigley C, Krag A; MicrobLiver Consortium; GALAXY Consortium. Thiele M, et al. Gastroenterology. 2023 Jun;164(7):1248-1260. doi: 10.1053/j.gastro.2023.02.023. Epub 2023 Feb 26. Gastroenterology. 2023. PMID: 36849086 Free article.
Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases.
Thiele M, Villesen IF, Niu L, Johansen S, Sulek K, Nishijima S, Espen LV, Keller M, Israelsen M, Suvitaival T, Zawadzki A, Juel HB, Brol MJ, Stinson SE, Huang Y, Silva MCA, Kuhn M, Anastasiadou E, Leeming DJ, Karsdal M, Matthijnssens J, Arumugam M, Dalgaard LT, Legido-Quigley C, Mann M, Trebicka J, Bork P, Jensen LJ, Hansen T, Krag A; MicrobLiver consortium; GALAXY consortium. Thiele M, et al. J Hepatol. 2024 Aug;81(2):345-359. doi: 10.1016/j.jhep.2024.03.035. Epub 2024 Mar 28. J Hepatol. 2024. PMID: 38552880 Free article. Review.
Fecal microbial load is a major determinant of gut microbiome variation and a confounder for disease associations.
Nishijima S, Stankevic E, Aasmets O, Schmidt TSB, Nagata N, Keller MI, Ferretti P, Juel HB, Fullam A, Robbani SM, Schudoma C, Hansen JK, Holm LA, Israelsen M, Schierwagen R, Torp N, Telzerow A, Hercog R, Kandels S, Hazenbrink DHM, Arumugam M, Bendtsen F, Brøns C, Fonvig CE, Holm JC, Nielsen T, Pedersen JS, Thiele MS, Trebicka J, Org E, Krag A, Hansen T, Kuhn M, Bork P; GALAXY and MicrobLiver Consortia. Nishijima S, et al. Cell. 2024 Nov 4:S0092-8674(24)01204-2. doi: 10.1016/j.cell.2024.10.022. Online ahead of print. Cell. 2024. PMID: 39541968 Free article.
[Payments, principles and priorities].
Bjørnelv GW, Melberg HO. Bjørnelv GW, et al. Among authors: melberg ho. Tidsskr Nor Laegeforen. 2023 Jun 12;143(9). doi: 10.4045/tidsskr.23.0210. Print 2023 Jun 13. Tidsskr Nor Laegeforen. 2023. PMID: 37341407 Free article. Norwegian. No abstract available.
Useful perspective on an overweight population.
Melberg HO. Melberg HO. Tidsskr Nor Laegeforen. 2023 Sep 19;143(13). doi: 10.4045/tidsskr.23.0593. Print 2023 Sep 26. Tidsskr Nor Laegeforen. 2023. PMID: 37753747 Free article. English, Norwegian. No abstract available.
Personalised human albumin in patients with cirrhosis and ascites: design and rationale for the ALB-TRIAL - a randomised clinical biomarker validation trial.
Torp N, Israelsen M, Coenraad M, Papp M, Shawcross D, Korenjak M, Angeli P, Laleman W, Juanola A, Gines P, Trebicka J, Krag A; MICROB-PREDICT Consortium. Torp N, et al. BMJ Open. 2024 Feb 14;14(2):e079309. doi: 10.1136/bmjopen-2023-079309. BMJ Open. 2024. PMID: 38355195 Free PMC article. Clinical Trial.
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial.
Israelsen M, Madsen BS, Torp N, Johansen S, Hansen CD, Detlefsen S, Andersen P, Hansen JK, Lindvig KP, Rasmussen DN, Thorhauge KH, Kjærgaard M, Karsdal M, Hansen T, Arumugam M, Trebicka J, Thiele M, Krag A; GALAXY; MicrobLiver Consortia. Israelsen M, et al. Lancet Gastroenterol Hepatol. 2023 Jun;8(6):523-532. doi: 10.1016/S2468-1253(23)00010-9. Epub 2023 Mar 6. Lancet Gastroenterol Hepatol. 2023. PMID: 36893774 Free PMC article. Clinical Trial.
46 results